Yan Yuanzhuo, Zhuo Huixian, Li Tengfei, Zhang Jintao, Tan Min, Chen Yue
Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan, China.
Front Oncol. 2024 Mar 21;14:1373606. doi: 10.3389/fonc.2024.1373606. eCollection 2024.
Prostate cancer(PCa), a leading global health concern, profoundly impacts millions of men worldwide. Progressing through two stages, it initially develops within the prostate and subsequently extends to vital organs such as lymph nodes, bones, lungs, and the liver. In the early phases, castration therapy is often employed to mitigate androgen effects. However, when prostate cancer becomes resistant to this treatment, alternative strategies become imperative. As diagnostic and treatment methodologies for prostate cancer continually advance, radioligand therapy (RLT) has emerged as a promising avenue, yielding noteworthy outcomes. The fundamental principle of RLT involves delivering radionuclide drugs to cancerous lesions through specific carriers or technologies. Subsequently, these radionuclide drugs release radioactive energy, facilitating the destruction of cancer cell tissues. At present, the positron emission tomography (PET) targeting PSMA has been widely developed for the use of diagnosis and staging of PCa. Notably, FDA-approved prostate-specific membrane antigen (PSMA) targeting agents, such as Ga-PSMA-11 and Lu-PSMA-617, represent significant milestones in enhancing diagnostic precision and therapeutic efficacy. This review emphasizes the current research status and outcomes of various radionuclide-labeled PSMA ligands. The objective is to provide valuable insights for the continued advancement of diagnostic and therapeutic approaches in the realm of prostate cancer.
前列腺癌（PCa）是全球主要的健康问题，对全球数百万男性产生深远影响。它经历两个阶段发展，最初在前列腺内发生，随后扩散到淋巴结、骨骼、肺和肝脏等重要器官。在早期阶段，常采用去势疗法来减轻雄激素的作用。然而，当前列腺癌对这种治疗产生抗性时，替代策略就变得至关重要。随着前列腺癌诊断和治疗方法的不断进步，放射性配体疗法（RLT）已成为一条有前景的途径，并取得了显著成果。RLT的基本原理是通过特定载体或技术将放射性核素药物输送到癌性病变部位。随后，这些放射性核素药物释放放射性能量，促进癌细胞组织的破坏。目前，针对PSMA的正电子发射断层扫描（PET）已广泛用于PCa的诊断和分期。值得注意的是，美国食品药品监督管理局（FDA）批准的靶向前列腺特异性膜抗原（PSMA）的药物，如Ga-PSMA-11和Lu-PSMA-617，是提高诊断准确性和治疗效果的重要里程碑。本综述强调了各种放射性核素标记的PSMA配体的当前研究现状和成果。目的是为前列腺癌领域诊断和治疗方法的持续发展提供有价值的见解。
